- Home
- JAZZ
as 05-09-2025 4:00pm EST
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
| Founded: | 2003 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN |
| Market Cap: | 6.1B | IPO Year: | 2007 |
| Target Price: | $181.85 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.51 | EPS Growth: | 49.21 |
| 52 Week Low/High: | $95.49 - $148.06 | Next Earning Date: | 05-06-2025 |
| Revenue: | $4,064,808,000 | Revenue Growth: | 5.76% |
| Revenue Growth (this year): | 7.6% | Revenue Growth (next year): | 3.47% |
Stock Insider Trading Activity of Jazz Pharmaceuticals plc (Ireland) (JAZZ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | JAZZ | Chairman & CEO | May 1 '25 | Sell | $118.18 | 1,500 | $176,350.00 | 439,307 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Apr 1 '25 | Sell | $123.75 | 1,500 | $185,625.00 | 439,307 | |
| Iannone Robert | JAZZ | EVP, Global Head of R&D & CMO | Mar 10 '25 | Sell | $138.41 | 2,403 | $332,604.52 | 79,621 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Mar 7 '25 | Sell | $137.81 | 1,140 | $157,103.40 | 7,012 | |
| Iannone Robert | JAZZ | EVP, Global Head of R&D & CMO | Mar 5 '25 | Sell | $139.11 | 7,080 | $981,297.72 | 79,621 | |
| Patil Neena M | JAZZ | EVP & Chief Legal Officer | Feb 27 '25 | Sell | $144.87 | 3,800 | $550,506.00 | 33,318 | |
| COZADD BRUCE C | JAZZ | Chairman & CEO | Feb 27 '25 | Sell | $144.25 | 6,500 | $937,625.00 | 439,307 | |
| Carr Patricia | JAZZ | SVP, Chief Accounting Officer | Feb 27 '25 | Sell | $144.04 | 5,586 | $805,842.21 | 7,012 |
Latest Jazz Pharmaceuticals plc (Ireland) News
JAZZ Breaking Stock News: Dive into JAZZ Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 hours ago
Jazz Pharmaceuticals plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Morningstar Research
a day ago
Analyst Report: Jazz Pharmaceuticals plc
Morningstar Research
2 days ago
Analyst Report: Jazz Pharmaceuticals plc
TipRanks
2 days ago
Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight
Insider Monkey
3 days ago
Jazz Pharmaceuticals (JAZZ): Among Billionaire Ray Dalio’s Bridgewater’s Stock Picks with Huge Upside Potential
MT Newswires
3 days ago
Morgan Stanley Cuts Price Target on Jazz Pharmaceuticals to $166 From $183, Keeps Overweight Rating
GuruFocus.com
3 days ago
Jazz Pharmaceuticals PLC (JAZZ) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...
Argus Research
3 days ago
JAZZ: Lowering target price to $122.00
Compare JAZZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JAZZ Jazz Pharmaceuticals plc (Ireland) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.